CORMEDIX INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
CORMEDIX INC. (CRMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $3.04 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-25.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2025-03-25
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $3.05.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-03-31 was $4.47, a 31.44% decline year-over-year.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2019-03-31 was $6.52, a 326.14% increase year-over-year.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2018-09-30 was $0.50, a 78.57% increase year-over-year.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $3.04, a 6.17% decline from fiscal 2023.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $3.24, a 11.72% increase from fiscal 2022.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $2.90, a 47.84% decline from fiscal 2021.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $5.56, a 54.87% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $3.04 10-K · filed 2025-03-25 | ||||
| 2024-09-30 | $3.00 10-Q · filed 2024-10-30 | ||||
| 2024-06-30 | $2.90 10-Q · filed 2024-08-14 | ||||
| 2023-12-31 | $3.24 10-K · filed 2025-03-25 | ||||
| 2023-09-30 | $3.43 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | $3.46 10-Q · filed 2023-08-08 | ||||
| 2022-12-31 | $2.90 10-K · filed 2024-03-12 | ||||
| 2022-09-30 | $2.93 10-Q · filed 2022-11-10 | ||||
| 2022-06-30 | $2.82 10-Q · filed 2022-08-11 | ||||
| 2022-03-31 | $3.05 10-Q · filed 2022-05-12 | ||||
| 2021-12-31 | $5.56 10-K · filed 2023-03-30 | ||||
| 2020-12-31 | $3.59 10-K · filed 2022-03-29 | ||||
| 2020-09-30 | $3.58 10-Q · filed 2020-11-05 | ||||
| 2020-06-30 | $3.58 10-Q · filed 2020-08-10 | ||||
| 2020-03-31 | $4.47 10-Q · filed 2020-05-11 | ||||
| 2019-12-31 | $6.11 10-K · filed 2021-03-30 | ||||
| 2019-09-30 | $6.71 10-Q · filed 2019-11-14 | ||||
| 2019-06-30 | $6.74 10-Q · filed 2019-08-14 | ||||
| 2019-03-31 | $6.52 10-Q · filed 2019-05-13 | ||||
| 2018-12-31 | $8.00 10-K · filed 2020-03-16 | ||||
| 2018-09-30 | $0.50 10-Q · filed 2018-11-14 | $0.31 10-Q · filed 2018-11-14 | |||
| 2018-06-30 | $0.30 10-Q · filed 2018-08-14 | ||||
| 2018-03-31 | $1.53 10-Q · filed 2019-05-13 | $0.31 10-Q · filed 2018-05-15 | |||
| 2017-09-30 | $0.28 10-Q · filed 2018-11-14 | $1.21 10-Q · filed 2018-11-14 | |||
| 2017-06-30 | $1.27 10-Q · filed 2018-08-14 | ||||
| 2017-03-31 | $1.42 10-Q · filed 2018-05-15 | ||||
| 2016-09-30 | $1.76 10-Q · filed 2017-11-09 | ||||
| 2016-06-30 | $1.64 10-Q · filed 2017-08-09 | ||||
| 2016-03-31 | $1.56 10-Q · filed 2017-05-10 | ||||
| 2015-12-31 | $3.46 10-K · filed 2016-03-15 | ||||
| 2014-12-31 | $1.50 10-K · filed 2016-03-15 | ||||
| 2014-03-31 | $1.49 10-Q · filed 2014-05-15 | ||||
| 2013-12-31 | $0.76 10-K · filed 2015-03-12 | ||||
| 2013-09-30 | $0.77 10-Q/A · filed 2014-03-04 | ||||
| 2013-06-30 | $0.77 10-Q/A · filed 2014-03-04 | ||||
| 2013-03-31 | $0.77 10-Q · filed 2014-05-15 | ||||
| 2012-12-31 | $0.46 10-K · filed 2014-03-31 | ||||
| 2012-09-30 | $0.32 10-Q/A · filed 2014-03-04 | ||||
| 2012-06-30 | $0.32 10-Q/A · filed 2014-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |